1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6B1C07ACDA536C741002585DF0047C92B
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-maximizing-impact-analytics-insights-teams-across-biopharma-organization-core-responsibilities-value-delivery-internal-branding-programs?opendocument
18
19opendocument
203.239.76.211
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Market Research, Analytics and Forecasting » Analytics

Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization: Core Responsibilities, Value Delivery and Internal Branding Programs

ID: 5641


Features:

16 Info Graphics

19 Data Graphics

350+ Metrics

12 Narratives


Pages/Slides: 43


Published: 2020


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Maximizing the Impact of Analytics and Insights Teams across the Biopharma Organization: Core Responsibilities, Value Delivery and Internal Branding Programs”

STUDY OVERVIEW

Analytics & Insights (A&I) teams within forward-looking biopharma companies are using ever-increasing access to data, advanced methodologies, and a meticulous approach to strategy to drive innovation across a growing spectrum of internal biopharma customer groups.

Best Practices, LLC undertook this benchmarking research to help A&I teams within biopharma companies make decisions to maximize its impact and enhance its standing not only with commercial teams and franchises, but also with medical affairs, HEOR, market access, corporate and other key internal customers.

The study examines how leading industry competitors leverage their analytics and talent to provide effective strategic consultation, grow service demand, and scale successes.

KEY TOPICS

  • Core A&I responsibilities and clients supported
  • Valuable strategic practices, skills and expertise areas
  • Internal branding programs
  • Top A&I obstacles, mistakes and lessons

KEY METRICS
  • Approximately what percentage of A&I team time is spent in support of each of the listed internal teams?
  • What role does your Analytics & Insights group play in fulfilling the listed organizational capabilities?
  • Which of the listed practices has your Analytics & Insights group used to provide greater value to your stakeholders?
  • How valuable are the listed professional experiences and soft skills for Analytics & Insights professionals to have in order to deliver the highest value to internal partners?
  • Which are the most critical knowledge areas and technical skills for Analytics & Insights team member to have in order to provide maximum value as a strategy partner to internal partners?
  • What do you see as the greatest challenges to the future success of your company’s Analytics & Insights function?
  • Has your Analytics & Insights function ever mounted an internal branding campaign to change or influence the perception of the function and the types of work it conducts?
  • How important were each of the listed objectives for your Analytics & Insights internal branding program within the organization?
  • Did the formal branding effort draw on support from a vendor?

SAMPLE KEY FINDINGS
  • A&I teams spend 72% of time supporting internal customers outside of brands:
    • Client support: A&I teams spend significant amounts of time supporting many customers beyond brands, including strategy planning, sales, franchises, market access and the C-suite. They spend only a tiny amount of time supporting HEOR and medical groups. A&I teams at mid-sized organizations may be responsible for supporting a wider number of clients and high-profile programs than in big pharma.
    • Face time: Mid pharma teams spend twice as much time supporting commercial development and strategy groups as large pharma, and 4x as much time supporting the C-suite.
METHODOLOGY

Best Practices, LLC engaged 44 Analytics and Insights professionals from 38 leading biopharma organizations in this research through a benchmark survey. Data in this study are segmented by mid vs. large pharma companies. Deep-dive interviews were conducted with selected benchmark participants to provide further insights. Over 85% of research participants serve at the director level or above.


Industries Profiled:
Medical Device; Biotech; Biopharmaceutical; Pharmaceutical; Manufacturing; Consumer Products; Diagnostic; Research; Consulting; Health Care; Clinical Research; Laboratories


Companies Profiled:
Alcon; Alkermes; Amgen; Arena Pharmaceuticals; AstraZeneca; Atara Biotherapeutics; Bayer; Bio-Rad Laboratories; Inc.; Biotest AG; Biotronik; Boehringer Ingelheim; B.Braun; Dermira; Edwards Lifesciences; GlaxoSmithKline ; Grünenthal; Janssen; Klosterfrau Healthcare Group; LEO Pharma; Lonza Inc.; MEDiSTRAVA; Merck; Merck Sharp & Dohme; Mitsubishi Tanabe Pharma; Momenta; Novartis; Pfizer; Qiagen; REGENXBIO Inc.; Sanofi; Santen; Scilex Pharmaceuticals; Seqirus; Servier; Sunovion; Takeda Pharmaceuticals; UCB Pharma; Vertex Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.